CA2341765A1 - Domaine de liaison d'arn de transfert - Google Patents

Domaine de liaison d'arn de transfert Download PDF

Info

Publication number
CA2341765A1
CA2341765A1 CA002341765A CA2341765A CA2341765A1 CA 2341765 A1 CA2341765 A1 CA 2341765A1 CA 002341765 A CA002341765 A CA 002341765A CA 2341765 A CA2341765 A CA 2341765A CA 2341765 A1 CA2341765 A1 CA 2341765A1
Authority
CA
Canada
Prior art keywords
peptide
trna
loop
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002341765A
Other languages
English (en)
Inventor
Christopher Hogue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mount Sinai Hospital Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2341765A1 publication Critical patent/CA2341765A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
    • C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
    • C12Y601/01001—Tyrosine-tRNA ligase (6.1.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)

Abstract

L'invention concerne un peptide sensiblement pur comprenant la séquence suivante: [ML] -X(3) -[LIVMC] - X(3)-[GMNEHK] -[MLFYI] -X(2) -[ST] - X(3)-[SAIG] -[RMIK] -X(2) -[MIVA] -X(2) -[GNRHK] -X-[IVLF] -X-[LIV] -[NDSRGAL] -X(3) -[LIVSQ] -X(2) -[PILVTAC] dans laquelle X représente un aminoacide quelconque. Fait aussi l'objet de cette invention un procédé permettant de déterminer si un acide nucléique comprend une boucle souche d'anticodon d'ARN de transfert. L'invention concerne aussi un procédé permettant d'identifier une substance se liant à un peptide, la liaison étant décelée par analyse des conjugats, d'une substance libre ou d'un peptide non complexe et un procédé permettant de déterminer si un composé de test est un agoniste ou un antagoniste d'une interaction de boucle souche d'anticodon de la synthétase d'ARN de transfert ou une interaction de boucle souche d'anticodon de protéine S4 ribosomique d'ARN de transfert. L'invention concerne en outre un procédé permettant d'obtenir un acide nucléique sensiblement pur comprenant une boucle souche d'anticodon d'ARN de transfert extraite d'un mélange de différents acides nucléiques. L'invention concerne finalement une composition pharmaceutique permettant d'inhiber l'interaction d'un ARN de transfert avec une synthétase d'ARN de transfert ou une protéine ribosomique ainsi que qu'autres aspects associés.
CA002341765A 1998-08-24 1999-08-24 Domaine de liaison d'arn de transfert Abandoned CA2341765A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9767098P 1998-08-24 1998-08-24
US60/097,670 1998-08-24
PCT/CA1999/000779 WO2000011141A2 (fr) 1998-08-24 1999-08-24 Domaine de liaison d'arn de transfert

Publications (1)

Publication Number Publication Date
CA2341765A1 true CA2341765A1 (fr) 2000-03-02

Family

ID=22264560

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002341765A Abandoned CA2341765A1 (fr) 1998-08-24 1999-08-24 Domaine de liaison d'arn de transfert

Country Status (3)

Country Link
AU (1) AU5367199A (fr)
CA (1) CA2341765A1 (fr)
WO (1) WO2000011141A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033276A1 (fr) * 1995-04-21 1996-10-24 Human Genome Sciences, Inc. Sequence nucleotidique du genome haemophilus influenzae rd, des fragments de ce dernier, ainsi que ses applications
GB9601067D0 (en) * 1996-01-19 1996-03-20 Smithkline Beecham Plc Novel compounds
GB9608001D0 (en) * 1996-04-18 1996-06-19 Smithkline Beecham Plc Novel compounds
US6107071A (en) * 1996-09-24 2000-08-22 Smithkline Beecham Corporation Histidinol dehydrogenase

Also Published As

Publication number Publication date
WO2000011141A2 (fr) 2000-03-02
WO2000011141A3 (fr) 2000-06-02
AU5367199A (en) 2000-03-14

Similar Documents

Publication Publication Date Title
DeLeo et al. Mapping sites of interaction of p47-phox and flavocytochrome b with random-sequence peptide phage display libraries.
Blond-Elguindi et al. Affinity panning of a library of peptides displayed on bacteriophages reveals the binding specificity of BiP
Chen et al. Binding of TFIIB to RNA polymerase II: mapping the binding site for the TFIIB zinc ribbon domain within the preinitiation complex
Clugston et al. Chirality of peptide bond-forming condensation domains in nonribosomal peptide synthetases: the C5 domain of tyrocidine synthetase is a DCL catalyst
CA2971402C (fr) Transglutaminases microbiennes, substrats pour celles-ci et procedes pour les utiliser
EP1718323B1 (fr) Peptidomimetiques de liaison et utilisations de ceux-ci
Kotik-Kogan et al. Structural basis for discrimination of L-phenylalanine from L-tyrosine by phenylalanyl-tRNA synthetase
US8198021B2 (en) Target and method for inhibition of bacterial RNA polymerase
US5856122A (en) Modification of pertussis toxin
Cronan Jr et al. [27] Biotinylation of proteins in vivo: A useful posttranslational modification for protein analysis
US6280964B1 (en) Binding sites for phosphotyrosine binding domains
US11280791B2 (en) System and method for identification and characterization of transglutaminase species
JP2005536184A (ja) ストレプトアビジン結合ペプチド
McFarland et al. Energetics and cooperativity of the hydrogen bonding and anchor interactions that bind peptides to MHC class II protein
Yang et al. Functional and crystal structure analysis of active site adaptations of a potent anti-angiogenic human tRNA synthetase
Li et al. The linker peptide of the ArsA ATPase
Spencer et al. The interaction of mitochondrial translational initiation factor 2 with the small ribosomal subunit
CA2341765A1 (fr) Domaine de liaison d'arn de transfert
WO1996021011A9 (fr) PEPTIDES SPECIFIQUES DU PREMIER DOMAINE SH-3 DE Crk
Vetter et al. Phosphorylation of serine residues affects the conformation of the calmodulin binding domain of human protein 4.1
WO2001083518A9 (fr) Molecules qui modulent la proteolyse dependant de l'ubiquitine et procedes d'identification de ces molecules
Farmery et al. Binding of GTP and GDP induces a significant conformational change in the GTPase domain of Ffh, a bacterial homologue of the SRP 54 kDa subunit
US8999894B2 (en) Nucleic acid-like proteins
YOO et al. Determination of the native form of FadD, the Escherichia coli fatty acyl-CoA synthetase, and characterization of limited proteolysis by outer membrane protease OmpT
Feldman et al. Phage display and crystallographic analysis reveals potential substrate/binding site interactions in the protein secretion chaperone CsaA from Agrobacterium tumefaciens

Legal Events

Date Code Title Description
FZDE Dead